Orchid Pharma’s Enmetazobactam Receives US FDA Approval

Chennai-based Orchid Pharma has received approval from the United States Food and Drug Administration (FDA) for its novel invention, ‘Enmetazobactam’. This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA). Enmetazobactam is the first completely invented-in-India beta lactamase inhibitor.

This US FDA approval paves the way for the introduction of enmetazobactam in the United States, the largest pharmaceutical market in the world. The product is expected to be launched within the next couple of quarters in the US market.

New Use of Exblifep

This New Drug Approval (NDA) allows the use of Exblifep (cefepime and enmetazobactam) as an injection for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex.

Being First in India

Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from US FDA. It is a significant development in addressing the global need for affordable and efficacious drugs to combat anti-microbial resistance (AMR).

Words from Orchid Pharma

• On this occasion, Manish Dhanuka, managing director - Orchid Pharma, said, “While EMA recommendation for grant of marketing authorization last month was a big achievement, the US FDA approval reinforces Orchid’s position on the safety of the drug and its innate need in the times of increasing antimicrobial resistance.
• First discovered in 2008, it has taken 16 years of pain staking work to get the product to market. During this time countless tests were done to establish its safety and efficacy and generate data for submission to regulatory authorities worldwide,” he added.

About Enmetazobactam

• Enmetazobactam was invented in India by Orchid and then out licensed to Allecra Therapeutics for further development.
• With the potential to save thousands of lives globally, this approval by US FDA is a testament to Indian ingenuity. 
• It is also a matter of great pride that as the pharmacy of the world, India has finally developed a new drug for the first time.

About Orchid

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. (Orchid) is a vertically integrated company spanning the entire pharmaceutical value chain with established credentials in research, manufacturing, and marketing.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!